HOME >> MEDICINE >> NEWS
UNC AIDS vaccine researchers awarded $12 million federal grant

Chapel Hill - Scientists at the University of North Carolina at Chapel Hill have won a five-year federal grant totaling more than $12 million to develop a safe and effective vaccine against HIV, the virus that causes AIDS.

The grant from the National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS, in Bethesda, Md., is one of only three large HIV Vaccine Research and Design grants awarded by the agency this year.

Over the next five years, a team led by Dr. Robert E. Johnston, professor of Microbiology and Immunology at the UNC-CH School of Medicine, will apply $12.35 million to study a novel vaccine method that is showing promise in early tests on monkeys.

The vaccine approach under study at UNC is built around a disabled, safe version of the Venezuelan equine encephalitis virus (VEE). In the wild, the tropical microbe infects horses and is sometimes carried to humans via mosquitoes.

Johnston and Microbiology/Immunology research associate professor Dr. Nancy Davis studied VEE for about a dozen years, developing candidate vaccines against the virus. Their work led them to believe it might be modified for use as a safe vaccine vector. Now it appears that their notion is correct.

Johnston and his colleagues are using a cocktail of VEE replicon particles (VRP) as a vector to carry the vaccine's molecular payload into the immune system. First, they modified the virus by removing about one-third of its genes. They then inserted genetic material taken from a pathogen, using as a test case simian immunodeficiency virus (SIV). In rhesus macaque monkeys, SIV causes a disease that is similar to AIDS in humans.

"The idea behind vaccination is to trick the body into thinking it's already had the disease once before. That's what vaccines do," Johnston explains. "They present the body with proteins from a disease organism and induce the body to respond immunologically in various ways to these antigens. Then when the individu
'"/>

Contact: Lynn Wooten
LWooten@unch.unc.edu
919-966-6046
University of North Carolina School of Medicine
10-Sep-1999


Page: 1 2 3

Related medicine news :

1. Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium
2. NIAID initiates trial of experimental avian flu vaccine
3. Study finds majority of women willing to accept cervical cancer vaccine for self and children
4. Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced
5. Earlier use of prostate cancer vaccines urged by Hopkins scientists
6. Researchers close in on breast cancer vaccine
7. EuroVacc 02 HIV vaccine trial begins in February 2005
8. Varicella vaccine effective on chicken pox; Impact on herpes zoster unclear
9. Pathogen-mimicking vaccine as strategy for cancer therapy
10. HIV vaccine trial breaks ground for future research
11. First US kidney cancer vaccine trial underway at Columbia

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UNC AIDS vaccine researchers awarded million federal grant

(Date:5/18/2013)... In a May 14, 2013 article entitled “Angelina Jolie ... Gene,” Fox News reported the movie star had opted ... a gene that doctors estimated gave her an 87 ... risk of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s ... a blog post entitled “A Patient’s Journey: Angelina Jolie” ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Today, ... insurance agents’ role in Marketplaces . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and Human Services (HHS) recently released a much-anticipated ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... 2013 TheBeautyPlace.com answers important questions about ... is not a result of stress, nutrient deficiency or ... Magazine, 70% of men suffer from male patterned baldness. ... renowned for hair transplant surgery, but additionally carries a ... known as Bosley Professional Strength. Their product line is ...
(Date:5/18/2013)... May 18, 2013 During Better Hearing ... should consider the legal protections they have, including the ... arise with their child’s treatment or hearing aid device, ... 1927, the American Speech-Language-Hearing Association has used the month ... to promote treatment, such as cochlear implants, which can ...
Breaking Medicine News(10 mins):Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
Cached News: